Preoperative serum levels of matrix metalloproteinase-2 (MMP-2) and survival of breast cancer among Korean women
A partir d'échantillons sanguins prélevés sur 303 patientes atteintes d'un cancer du sein (durée médiane de suivi : 4,24 ans), cette étude coréenne évalue, en fonction du statut des récepteurs aux œstrogènes et du grade histologique ou nucléaire de la tumeur, l'association entre les niveaux sériques pré-opératoires des métalloprotéases matricielles 2 et la survie des patientes
Background : MMP-2 has been thought of as a predictor of recurrence or metastasis risk or prognostic markers in cancer. We evaluated whether preoperative serum levels of matrix metalloproteinase-2 (MMP-2) work as a prognostic biomarker in breast cancer prognosis. Methods : Preoperative serum levels of MMP-2 were measured with enzyme-linked immunosorbent assay (ELISA) in 303 histologically confirmed breast cancer patients. The median follow-up time for all patients was 4.24 years. The relationship of MMP-2 to survival was investigated using Cox's proportional hazard regression model adjusted for the TNM stage and estrogen receptor (ER) status. Results:In the multivariate analysis, disease-free survival (DFS) was worse among patients with the third tertile of MMP-2 level compared to the first tertile of MMP-2 level (hazard ratio (HR)=1.80, 95% confidence interval (CI)=1.04-3.11, P=0.04). However, when the patients were stratified by age, ER status, histological grade, and nuclear grade, inverse correlation was shown between serum MMP-2 levels and prognostic factors and the associations between MMP-2 and DFS were only significant among patients with poor prognostic factors (HR=2.75, 95% CI=1.32-5.73 in ER negative, HR=2.90 and 95% CI=1.42-5.92 in histological grade III, and HR=2.61 and 95% CI=1.26-5.39 in nuclear grade III). Conclusions:Our results suggest that the preoperative serum levels of MMP-2 were associated with the survival in breast cancer patients in ER negative, higher histological grade, or higher nuclear grade breast cancers. Impact:Our results indicate that serum levels of MMP-2 may play a role as prognostic biomarker in breast cancer survival.
Cancer Epidemiology Biomarkers & Prevention , résumé, 2012